Prof. Marco Falasca
School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, Australia.
Special Issue Introduction
Pancreatic cancer is an increasingly common malignancy that has benefited very little from research advancements and new discoveries, as it remains largely an untreatable disease with a 5-year survival rate lower than 9%. The reasons for this setback are searched in the lack of specific early-stage symptomatology, leading to a late diagnosis and consequently limited option of treatment, as well as resistance to chemo- and radiotherapy and high metastatic potential. Disruption of cell signaling pathways and genetic alterations involving activation of oncogenes and blocking of tumor suppressors are well known to contribute to the start and progression of this tumor. Yet, new understanding and insight, particularly guiding towards new strategies for improved therapies, is eagerly awaited. This Special Issue intends to publish original research, expert opinions, and reviews on basic, translational and clinical studies connected to different aspects of pancreatic cancer cell biology, genomics, precision medicine, medical oncology, radiation therapy, and surgery.
Pancreatic Cancer, biology, genomics, precision medicine, radiation therapy
30 Apr 2022